NUTH, The Netherlands and SAN DIEGO, May 24, 2017 -- Fortimedix Surgical today announced the appointment of David Castiglioni as Vice President of Sales in the United States. Under Mr. Castiglioni’s leadership, the Fortimedix Surgical commercial team will further expand sales of the symphonX™ Surgical Platform, the company’s flagship product and the world’s lowest profile single-port surgery solution.
“Fortimedix Surgical is well-positioned to achieve its strategic goals for near- and long-term growth with the appointment of Mr. Castiglioni,” said Wout Bijker, CEO. “David brings a wealth of knowledge within the medical device space, particularly around market introductions of disruptive technologies, and we will benefit greatly from his leadership and expertise.”
Mr. Castiglioni has over 18 years of medical device sales and marketing experience, including senior leadership roles at Intuitive Surgical and Abbott Vascular, where he built and led cohesive sales teams to success within a variety of medical device markets in the United States. He joins Fortimedix Surgical from MiMedix where he served as Vice President of Surgical Sales, North America.
About symphonX™
symphonX™ is the world’s first single-port surgery solution compatible with a standard 15mm laparoscopic trocar. Emulating conventional, multi-port laparoscopy makes symphonX™ easy to use and enables surgeons to perform procedural steps ergonomically, allowing for a comfortable and secure single-port approach. symphonX™ is poised to deliver on the promise of single-port surgery, including fewer port-site complications, less post-operative pain, faster recovery and exceptional cosmesis, elevating the standard of care in laparoscopy.
About Fortimedix Surgical
Fortimedix Surgical is a fast growing medical device company, aiming to challenge the status quo in minimally invasive surgery by creating novel devices that capture the claimed benefits of single-port surgery. The company is headquartered in Nuth, The Netherlands, and has a U.S. subsidiary in San Diego, CA. With a strong history as a global market leader in contract stent manufacturing, Fortimedix has been a trusted partner in the medical device industry for over 15 years. Fortimedix Surgical is committed to driving the evolution of minimally invasive surgery through smart innovation across surgical specialties to improve the quality of life of patients throughout the world.
For more information, please visit www.fortimedixsurgical.com
Forward-Looking Statements
Certain statements herein include “forward-looking” statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward-looking statements involve risks and uncertainties, including, but not limited to, the protection of intellectual property, changes to governmental regulation of medical devices, the introduction of new products into the marketplace by competitors, changes to the competitive environment, the acceptance of new products in the marketplace, conditions of the surgical industry and economic and political conditions globally. Actual results may differ materially from those contemplated or implied by the forward-looking statements. The forward-looking statements speak only as of the date of this release and Fortimedix Surgical assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.
For media inquiries, please contact: Fortimedix Surgical B.V., Monique Biermans, [email protected], +31 (0)6 24 676 376 Digital press release available at: www.fortimedixsurgical.com/news-events/news-events Lazar Partners, Chantal Beaudry, [email protected], or Amy Feldman, [email protected], +1 (212) 867-1762


Google Disrupts Major Residential Proxy Network IPIDEA
Meta Stock Surges After Q4 2025 Earnings Beat and Strong Q1 2026 Revenue Outlook Despite Higher Capex
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom
The Maire - EuroChem Case: Three Lessons for Global Business
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 



